National Cancer Institute, Naples — CureCurrent

How to interpret these research links

Connected source records

The exact organization name National Cancer Institute, Naples appears in 32 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials32

Recruiting shown5

Roles2

SourceClinicalTrials.gov

Clinical trials

32 shown

REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)NCT07302451 · lead sponsor · 2026-02-23

Financial Toxicity in Patients With Early-stage Breast CancerNCT07354165 · lead sponsor · 2025-09-30

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.NCT05817227 · lead sponsor · 2022-05-19

PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)NCT04854213 · lead sponsor · 2021-10-06

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)NCT04893785 · lead sponsor · 2021-06-15

The Study is Observational and Retrospective: Lifestyle, BMI and Activity Physical.NCT06866093 · lead sponsor · 2023-09-04

ACTIVE_NOT_RECRUITING

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.NCT05818865 · lead sponsor · 2021-01-18

ACTIVE_NOT_RECRUITING

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.NCT04139772 · lead sponsor · 2019-09-01

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)NCT03975114 · lead sponsor · 2018-12-20

Diet, Exercise and Vitamin D in Breast Cancer RecurrenceNCT02786875 · lead sponsor · 2016-11-04

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerNCT02633189 · lead sponsor · 2016-04-01

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First ChemotherapyNCT02035683 · lead sponsor · 2013-10-01

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine TumorsNCT01755182 · lead sponsor · 2013-07-01

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung CancerNCT01656551 · lead sponsor · 2012-08-01

MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung CancerNCT01405586 · lead sponsor · 2011-03-01

ELBA: Exemestane and Lapatinib in Advanced Breast CancerNCT01005641 · lead sponsor · 2009-12-01

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC PatientsNCT00526643 · lead sponsor · 2007-11-01

VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast CancerNCT00431704 · lead sponsor · 2007-10-01

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast CancerNCT00434031 · lead sponsor · 2007-09-01

STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing StudyNCT00526396 · lead sponsor · 2007-09-01

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung CancerNCT00349219 · lead sponsor · 2006-12-01

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate CancerNCT00415779 · lead sponsor · 2006-07-01

CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung CancerNCT00330746 · lead sponsor · 2005-11-01

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung CancerNCT00345059 · lead sponsor · 2005-05-01

HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.NCT00412022 · lead sponsor · 2004-03-01

BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast CancerNCT00540800 · lead sponsor · 2004-02-01

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant TreatmentNCT00331097 · lead sponsor · 2003-07-01

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLCNCT00385606 · lead sponsor · 2003-01-01

HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast CancerNCT00401427 · lead sponsor · 2002-11-01

MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung CancerNCT00401492 · lead sponsor · 2002-06-01

G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly PatientsNCT00401609 · lead sponsor · 2000-11-01

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · collaborator · 2015-02-24

Sponsor roles

lead sponsor31

collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.